Pipeline
Therapeutic Area
Description
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT1A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder, the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd. Sunovion discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube® platform and associated artificial intelligence algorithms. Ulotaront is being studied in a global Phase 3 development program for schizophrenia (DIAMOND) with additional indications under consideration. The U.S. FDA granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Description
Vibegron is being investigated in COURAGE, a phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH).
Description
SEP-4199 is is a non-racemic ratio of amisulpride under investigation for the treatment of bipolar depression. The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the U.S. for the treatment for schizophrenia and other psychiatric conditions.
Description
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT11A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder, the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd.
Description
Ulotaront (SEP-363856) is a TAAR1 agonist with 5-HT11A agonist activity that is under investigation for the treatment of schizophrenia, generalized anxiety disorder, the adjunctive treatment of major depressive disorder and other CNS conditions. Ulotaront is being jointly developed and commercialized in partnership with Otsuka Pharmaceuticals Co. Ltd.
Neurology
Description
test111
Oncology
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Oncology
Description
test111
Psychiatry
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Psychiatry
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Psychiatry
Description
test111
Psychiatry
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Psychiatry
Description
test111
Oncology
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Oncology
Description
test111
Oncology
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Regenerative Medicine
Description
test111
Regenerative Medicine
Description
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
Additional Information
Donec sed odio dui. Praesent commodo cursus magna, vel scelerisque nisl consectetur et.
KEY: * Otsuka partnered assets
Medical professionals can visit our contact page to email a request for more information about clinical trial participation.